Bausch + Lomb (BLCO) Competitors

Zimmer Biomet (NYSE:ZBH) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Which has higher valuation & earnings, ZBH or BLCO?

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.68B	2.66	$903.70M	$4.11	25.07
Bausch + Lomb	$4.79B	1.05	-$317M	-$0.78	-18.17

Do institutionals and insiders hold more shares of ZBH or BLCO?

88.9% of Zimmer Biomet shares are owned by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are owned by institutional investors. 1.4% of Zimmer Biomet shares are owned by insiders. Comparatively, 0.8% of Bausch + Lomb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Does the media prefer ZBH or BLCO?

In the previous week, Zimmer Biomet had 40 more articles in the media than Bausch + Lomb. MarketBeat recorded 43 mentions for Zimmer Biomet and 3 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 0.91 beat Bausch + Lomb's score of 0.39 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	22 Very Positive mention(s)	1 Positive mention(s)	12 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, ZBH or BLCO?

Zimmer Biomet has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Is ZBH or BLCO more profitable?

Zimmer Biomet has a net margin of 10.51% compared to Bausch + Lomb's net margin of -5.58%. Zimmer Biomet's return on equity of 12.76% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	10.51%	12.76%	7.21%
Bausch + Lomb	-5.58%	2.33%	1.12%

Do analysts rate ZBH or BLCO?

Zimmer Biomet presently has a consensus target price of $111.44, suggesting a potential upside of 8.16%. Bausch + Lomb has a consensus target price of $15.56, suggesting a potential upside of 9.78%. Given Bausch + Lomb's higher possible upside, analysts plainly believe Bausch + Lomb is more favorable than Zimmer Biomet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35
Bausch + Lomb	1 Sell rating(s)	6 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Zimmer Biomet beats Bausch + Lomb on 15 of the 16 factors compared between the two stocks.